Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
CymaBay Therapeutics revenue
CymaBay Therapeutics's revenue is $31.1 million.
What is CymaBay Therapeutics's revenue?
- CymaBay Therapeutics peak revenue was $31.1M in 2023.
- CymaBay Therapeutics's revenue growth from 2012 to 2023 is 918.79%.
- CymaBay Therapeutics has 41 employees, and the revenue per employee ratio is $757,878.
- CymaBay Therapeutics's peak quarterly revenue was $31.0M in 2023(q2).
- CymaBay Therapeutics annual revenue for 2017 was 10.0M, 227.87% growth from 2012.
- CymaBay Therapeutics annual revenue for 2023 was 31.1M, 210.73% growth from 2017.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
CymaBay Therapeutics historical revenue
CymaBay Therapeutics's peak revenue was $31.1M in 2023. The peak quarterly revenue was $31.0M in 2023(q2).
CymaBay Therapeutics's revenue increased from $3.0m in 2012 to $31.1M currently. That's a 918.79% change in annual revenue.
CymaBay Therapeutics annual revenue
CymaBay Therapeutics annual revenue over time
| Fiscal year / year | CymaBay Therapeutics revenue |
|---|---|
| 2012 | $3.1M |
| 2017 | $10.0M |
| 2023 | $31.1M |
CymaBay Therapeutics jobs nearby
Do you work at CymaBay Therapeutics?
Did CymaBay Therapeutics meet its revenue projections?
CymaBay Therapeutics financial information
| CEO | Sujal Shah |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 41 |
| Date Founded | 1988 |
| Headquarters | Newark, California |
| Number of Locations | 1 |
| Revenue | $31.1M |
| Net Income | -$106,001,000 |
| PE Ratio | -3.31 |
| Market Capitalization | $348.3M |
| Total Assets | $141,852,000 |
| Ticker | CBAY |
CymaBay Therapeutics jobs you might like
CymaBay Therapeutics financing
CymaBay Therapeutics received early financing of $10.0M on 2000-01-01.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $10M | 01/2000 |
| Series A | $27M | 08/2003 |
| Series B | $44M | 12/2004 |
| Series C | $10M | 08/2006 |
| Series D | $32M | 04/2007 |
| Debt Financing | $27.7M | 07/2009 |
| Series E | $8.6M | 11/2009 |
| Series Unknown | $26.8M | 10/2013 |
| Debt Financing | $5M | 12/2013 |
| Post Ipo Debt | $325K | 08/2015 |
| Post Ipo Debt | $100M | 08/2021 |
| Post Ipo Debt | $75M | 11/2021 |
CymaBay Therapeutics investors
| Investors | Security type |
|---|---|
| Bay City Capital | Series A |
| CDP Capital Technology Ventures | Series A |
| Biotech Turnaround Fund (BTF) | Series A |
| Charter Venture Group | Series A |
| Bay City Capital | Series B |
| Birchmere Ventures | Series B |
| Novo Holdings A | Series B |
| Versant Ventures | Series B |
| Venrock | Series B |
| Alta Partners | Series B |
| KBC | Series B |
| Novo Ventures | Series D |
| Venrock | Series D |
| ALLIANCEBERNSTEIN L.P. | Series D |
| Alta Partners | Series D |
| Deerfield Capital Management | Series D |
| Vantage Point Capital Partners | Series D |
| Bay City Capital | Series D |
| Johnson & Johnson Development Corporation | Series D |
| Birchmere Ventures | Series D |
| Pictet Group | Series D |
| Merlin Biomed | Series D |
| Versant Ventures | Series D |
| KBC | Series D |
| T. Rowe Price Group, Inc. | Series D |
| Biotech Turnaround Fund (BTF) | Series D |
| Vantage Point Capital Partners | Series E |
| Bay City Capital | Series E |
| Birchmere Ventures | Series E |
| Pictet Group | Series E |
| Novo Ventures | Series E |
| Merlin Biomed | Series E |
| Charter Life Sciences | Series E |
| Versant Ventures | Series E |
| Venrock | Series E |
| Alta Partners | Series E |
| KBC | Series E |
| Next Chapter Holdings | Series E |
| Oxford Finance LLC | Debt Financing |
| Silicon Valley Bank | Debt Financing |
| Abingworth | Post Ipo Debt |
Search for jobs
CymaBay Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of CymaBay Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about CymaBay Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at CymaBay Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by CymaBay Therapeutics. The data presented on this page does not represent the view of CymaBay Therapeutics and its employees or that of Zippia.
CymaBay Therapeutics may also be known as or be related to CYMABAY THERAPEUTICS INC., CymaBay Therapeutics, CymaBay Therapeutics Inc, CymaBay Therapeutics, Inc., Cymabay Therapeutics Inc and Cymabay Therapeutics, Inc.